Parkinson’s disease variant detection and disclosure: PD GENEration, a North American study
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Variants in seven genes (LRRK2, GBA1, PRKN, SNCA, PINK1, PARK7 and VPS35) have been formally adjudicated as causal contributors to Parkinson’s disease; however, individuals with Parkinson’s disease are often unaware of their genetic status since clinical testing is infrequently offered. As a result, genetic information is not incorporated into clinical care, and variant-targeted precision medicine trials struggle to enrol people with Parkinson’s disease. Understanding the yield of genetic testing using an established gene panel in a large, geographically diverse North American population would help patients, clinicians, clinical researchers, laboratories and insurers better understand the importance of genetics in approaching Parkinson’s disease. PD GENEration is an ongoing multi-centre, observational study (NCT04057794, NCT04994015) offering genetic testing with results disclosure and genetic counselling to those in the US (including Puerto Rico), Canada and the Dominican Republic, through local clinical sites or remotely through self-enrolment. DNA samples are analysed by next-generation sequencing including deletion/duplication analysis (Fulgent Genetics) with targeted testing of seven major Parkinson’s disease-related genes. Variants classified as pathogenic/likely pathogenic/risk variants are disclosed to all tested participants by either neurologists or genetic counsellors. Demographic and clinical features are collected at baseline visits. Between September 2019 and June 2023, the study enrolled 10 510 participants across >85 centres, with 8301 having received results. Participants were: 59% male; 86% White, 2% Asian, 4% Black/African American, 9% Hispanic/Latino; mean age 67.4 ± 10.8 years. Reportable genetic variants were observed in 13% of all participants, including 18% of participants with one or more ‘high risk factors’ for a genetic aetiology: early onset (<50 years), high-risk ancestry (Ashkenazi Jewish/Basque/North African Berber), an affected first-degree relative; and, importantly, in 9.1% of people with none of these risk factors. Reportable variants in GBA1 were identified in 7.7% of all participants; 2.4% in LRRK2; 2.1% in PRKN; 0.1% in SNCA; and 0.2% in PINK1, PARK7 or VPS35 combined. Variants in more than one of the seven genes were identified in 0.4% of participants. Approximately 13% of study participants had a reportable genetic variant, with a 9% yield in people with no high-risk factors. This supports the promotion of universal access to genetic testing for Parkinson’s disease, as well as therapeutic trials for GBA1 and LRRK2-related Parkinson’s disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite most cases of PD resulting from sporadic mutations, inherited PD remains a legitimate concern and is highly correlated with many genes, including Synuclein alpha (SNCA), Leucine-rich Repeat Kinase 2 (LRRK2), Parkin (PRKN), PTEN Induced Kinase 1 (PINK1), VPS35 Retromer Complex Component (VPS35), and Vacuolar Protein Sorting 13 Homolog C (VPS13C) [137].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [137]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594
MDS clinical diagnostic criteria for Parkinson’s disease
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., et al. (2015) · Movement Disorders · doi:10.1002/mds.26424 · Cited by 7,653
Self-citationEpidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
Bloem, B. R., Okun, M. S., & Klein, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00218-x · Cited by 3,920
Nalls, M. A., Blauwendraat, C., Vallerga, C. L., Heilbron, K., Bandres-Ciga, S., Chang, D., Tan, M., Kia, D. A., Noyce, A. J., Xue, A., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30320-5 · Cited by 2,454
Self-citationParkinson's disease: from monogenic forms to genetic susceptibility factors
Lesage, S., & Brice, A. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp012 · Cited by 945
Strande, N. T., Riggs, E. R., Buchanan, A. H., Ceyhan-Birsoy, O., DiStefano, M., Dwight, S. S., Goldstein, J., Ghosh, R., Seifert, B. A., Sneddon, T. P., et al. (2017) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2017.04.015 · Cited by 567
Duran, R., Mencacci, N. E., Angeli, A. V., Shoai, M., Deas, E., Houlden, H., Mehta, A., Hughes, D., Cox, T. M., Deegan, P., et al. (2013) · Movement Disorders · doi:10.1002/mds.25248 · Cited by 146
Self-citationAlcalay, R. N., Caccappolo, E., Mejia-Santana, H., Tang, M. X., Rosado, L., Ross, B. M., Verbitsky, M., Kisselev, S., Louis, E. D., Comella, C., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.194 · Cited by 145
Self-citationFeatures of GBA-associated Parkinson’s disease at presentation in the UK Tracking Parkinson’s study
Malek, N., Weil, R. S., Bresner, C., Lawton, M. A., Grosset, K. A., Tan, M., Bajaj, N., Barker, R. A., Burn, D. J., Foltynie, T., et al. (2018) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-317348 · Cited by 133
Genetic Forms of Parkinson's Disease
Kim, C., & Alcalay, R. (2017) · Seminars in Neurology · doi:10.1055/s-0037-1601567 · Cited by 120 · cited 15×
“Additional details regarding gene variants observed are described in Figs 2and 3and the Supplementary Table 5.”
BackgroundInfluentialSelf-citationThe Rostock International Parkinson's Disease ( ROPAD ) Study: Protocol and Initial Findings
Skrahina, V., Gaber, H., Vollstedt, E., Förster, T. M., Usnich, T., Curado, F., Brüggemann, N., Paul, J. J., Bogdanović, X., Zülbahar, S., et al. (2020) · Movement Disorders · doi:10.1002/mds.28416 · Cited by 115 · cited 4×
“3,6,7 For example, while as expected, GBA1 and LRRK2 variants were more common among people of Ashkenazi Jewish ancestry compared with those without any high-risk ancestries, most who possessed these variants were non-Ashkenazi Jewish (Supplementary Table 4).”
BackgroundResultInfluentialPal, G., Mangone, G., Hill, E. J., Ouyang, B., Liu, Y., Lythe, V., Ehrlich, D., Saunders‐Pullman, R., Shanker, V., Bressman, S., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26302 · Cited by 104 · cited 1×
“…genetic status 11,18 ; (ii) different genetic forms of Parkinson’s disease can have strikingly different prognoses 4 ; (iii) emerging evidence that genotype may be relevant for aspects of clinical care 28 ; and (iv) gen-etic status can determine eligibility for precision medicine clinical trials.”
BackgroundSelf-citationGBA p.T369M substitution in Parkinson disease: Polymorphism or association? A meta-analysis
Mallett, V. M., Ross, J. P., Alcalay, R. N., Ambalavanan, A., Sidransky, E., Dion, P. A., Rouleau, G. A., & Gan‐Or, Z. (2016) · Neurology Genetics · doi:10.1212/nxg.0000000000000104 · Cited by 96
Self-citationGenetic analysis of Mendelian mutations in a large UK population-based Parkinson’s disease study
Tan, M. M. X., Malek, N., Lawton, M. A., Hubbard, L., Pittman, A. M., Joseph, T., Hehir, J., Swallow, D. M. A., Grosset, K. A., Marrinan, S. L., et al. (2019) · Brain · doi:10.1093/brain/awz191 · Cited by 81 · cited 1×
“8,9 The c.6055G > A (p.Gly2019Ser) variant was the predominant abnormal finding in LRRK2 , similar to reports of Parkinson’s disease genetic testing results in other European-based b A s h k e n a z i J e w i s h , S p a n i s h B a s q u e , N o r t h A f r i c a n B e r b e r .”
ResultPrevalence of ten LRRK2 variants in Parkinson's disease: A comprehensive review
Simpson, C., Vinikoor-Imler, L. C., Nassan, F. L., Shirvan, J. C., Lally, C. A., Dam, T., & Maserejian, N. N. (2022) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2022.05.012 · Cited by 81 · cited 1×
“13 There are several clinical reasons why individuals with Parkinson’s disease might wish to have genetic testing: to aid in diagnosis, to answer the question, ‘Why did I get Parkinson’s disease?’”
BackgroundBenitez, B. A., Davis, A. A., Jin, S. C., Ibanez, L., Ortega-Cubero, S., Pastor, P., Choi, J., Cooper, B., Perlmutter, J. S., & Cruchaga, C. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0097-0 · Cited by 75 · cited 1×
“3,6,7 For example, while as expected, GBA1 and LRRK2 variants were more common among people of Ashkenazi Jewish ancestry compared with those without any high-risk ancestries, most who possessed these variants were non-Ashkenazi Jewish (Supplementary Table 4).”
BackgroundAlcalay, R. N., Kehoe, C. M., Shorr, E., Battista, R., Hall, A., Simuni, T., Marder, K. S., Wills, A.-M. A., Naito, A., Beck, J. C., et al. (2019) · Genetics in Medicine · doi:10.1038/s41436-019-0684-x · Cited by 68 · cited 1×
“5,11 Previous studies have shown a greater likelihood of positive (abnormal) gene test results among those with an earlier age at onset (AAO), positive family history or certain ancestry such as Ashkenazi Jewish, Spanish Basque or North African Berber.”
BackgroundSelf-citationGenetic Etiologies for Chronic Kidney Disease Revealed through Next-Generation Renal Gene Panel
Bleyer, A. J., Westemeyer, M. A., Xie, J., Bloom, M. S., Brossart, K., Eckel, J. J., Jones, F., Molnar, M. Z., Kotzker, W. R., Anand, P., et al. (2022) · American Journal of Nephrology · doi:10.1159/000522226 · Cited by 61
Self-citationAssessing the relationship between monoallelic PRKN mutations and Parkinson’s risk
Lubbe, S. J., Bustos, B. I., Hu, J., Krainc, D., Joseph, T., Hehir, J., Tan, M., Zhang, W., Escott-Price, V., Williams, N. M., et al. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddaa273 · Cited by 58 · cited 1×
“26 VUS are not disclosed to participants but are catalogued for research use and shared with a global consortium of Parkinson’s disease geneticists and clinicians to centralize and harmonize discussions of VUS identified across multiple studies (ClinGen Parkinson’s Disease Variant Curation Expert…”
BackgroundSelf-citationEmerging Targeted Therapeutics for Genetic Subtypes of Parkinsonism
Schneider, S. A., Hizli, B., & Alcalay, R. N. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00920-8 · Cited by 44
Self-citationProviding genetic testing and genetic counseling for Parkinson’s disease to the community
Cook, L. P., Verbrugge, J., Schwantes-An, T.-H. L., Schulze, J., Beck, J. C., Naito, A., Hall, A., Chan, A. K., Casaceli, C. J., Marder, K. S., et al. (2023) · Genetics in Medicine · doi:10.1016/j.gim.2023.100907 · Cited by 31 · cited 2×
“…on the feasibility and safety of counselling/return of results through the local neurologist versus centralized genetic counselors (pilot phase), 18 then the expansion of the study to multiple clinical sites in the US (clinical phase; Table 4), followed by a simplified study protocol to permit…”
BackgroundSelf-citationThe commercial genetic testing landscape for Parkinson's disease
Cook, L. P., Schulze, J., Verbrugge, J., Beck, J. C., Marder, K. S., Saunders-Pullman, R. J., Klein, C., Naito, A., Alcalay, R. N., Brice, A., et al. (2021) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2021.10.001 · Cited by 30 · cited 1×
“14 In addition, the seven genes on this panel were previously adjudicated by an independent panel of Parkinson’s disease experts using a recently developed framework supported by the National Institutes of Health (NIH)-funded Clinical Genome Resource (ClinGen) 20 that found sufficient evidence to…”
MethodSelf-citationResolving misalignment interference for NGS-based clinical diagnostics
Lee, C.-Y., Yen, H.-Y., Zhong, A. W., & Gao, H. (2020) · Human Genetics · doi:10.1007/s00439-020-02216-5 · Cited by 27 · cited 1×
“22 To verify homozygosity for variants in the GBA1 gene, for each exon, the lab utilizes two sets of primers to account for possible allele dropout.”
MethodParkinson's Disease: Patients’ Knowledge, Attitudes, and Interest in Genetic Counseling
Maloney, K. A., Alaeddin, D. S., von Coelln, R., Dixon, S., Shulman, L. M., Schrader, K., & Guan, Y. (2018) · Journal of Genetic Counseling · doi:10.1007/s10897-018-0239-3 · Cited by 26 · cited 1×
“Motivations to return genetic results to people with Parkinson’s disease include: (i) people are interested in knowing their genetic status 11,18 ; (ii) different genetic forms of Parkinson’s disease can have strikingly different prognoses 4 ; (iii) emerging evidence that genotype may be relevant…”
BackgroundLuca, D. G. D., Macklin, E. A., Hodgeman, K., Lopez, G., Pothier, L. M., Callahan, K. F., Lowell, J., Chan, J. G. M., Videnović, A., Lungu, C., et al. (2023) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000200113 · Cited by 20
Self-citationGenome Sequencing in the Parkinson Disease Clinic
Hill, E. J., Robak, L. A., Al‐Ouran, R., Deger, J., Fong, J. C., Vandeventer, P. J., Schulman, E., Rao, S., Saade, H., Savitt, J. M., et al. (2022) · Neurology Genetics · doi:10.1212/nxg.0000000000200002 · Cited by 19 · cited 2×
“3,6,7 For example, while as expected, GBA1 and LRRK2 variants were more common among people of Ashkenazi Jewish ancestry compared with those without any high-risk ancestries, most who possessed these variants were non-Ashkenazi Jewish (Supplementary Table 4).”
BackgroundSelf-citationThe Genetic Testing Experience of Individuals with Parkinson's Disease
Richards, S., Mu, W., Nusbaum, R. H., Lincoln, K., & Solimine, J. F. (2022) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13641 · Cited by 3
Cited by
Uncovering the genetic basis of Parkinson's disease globally: from discoveries to the clinic
Lim, S., Tan, A. H., Ahmad‐Annuar, A., Okubadejo, N. U., Lohmann, K., Morris, H. R., Toh, T. S., Tay, Y. W., Lange, L. M., Bandrés‐Ciga, S., et al. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00378-8 · Cited by 98
“The yield also depends on the number of genes tested, 10 for example whether focusing on established PD-linked genes 12,50 or screening a larger neurodegenerative panel with 50 genes.”
Self-citationDorsey, E. R., Miranda, B. R. D., Hussain, S., Bloem, B. R., Elbaz, A., Llibre‐Guerra, J. J., Lo, R. Y., Goldman, S. M., & Tanner, C. M. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00287-x · Cited by 55
Updated MDSGene review on the clinical and genetic spectrum of LRRK2 variants in Parkinson´s disease
Krüger, C., Lim, S., Buhrmann, A., Fahrig, F. L., Gabbert, C., Bahr, N., Madoev, H., Marras, C., Klein, C., & Lohmann, K. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-00881-9 · Cited by 52
Self-citationClassification and Genotype–Phenotype Relationships of GBA1 Variants: MDSGene Systematic Review
Rossi, M., Schaake, S., Usnich, T., Boehm, J., Steffen, N., Schell, N., Krüger, C., Gül, T., Bahr, N., Kleinz, T., et al. (2025) · Movement Disorders · doi:10.1002/mds.30141 · Cited by 41
“6,42 43-46 An earlier age of disease onset than sporadic PD has been reported in GBA1 -related PD. 5,47,48 Data from the Rostock Parkinson ’ s disease observational clinical study aiming to determine the frequency and spectrum of genetic variants contributing to PD in a large international cohort…”
Self-citationGenetics of Parkinson's Disease: From Causes to Treatment
Westenberger, A., Brüggemann, N., & Klein, C. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041774 · Cited by 42
Metadata
- Authors
- Cook, L., Verbrugge, J., Schwantes-An, T.-H., Schulze, J., Foroud, T., Hall, A., Marder, K. S., Mata, I. F., Mencacci, N. E., Nance, M. A., Schwarzschild, M. A., Simuni, T., Bressman, S., Wills, A.-M., Fernandez, H. H., Litvan, I., Lyons, K. E., Shill, H. A., Singer, C., Tropea, T. F., Vanegas Arroyave, N., Carbonell, J., Cruz Vicioso, R., Katus, L., Quinn, J. F., Hodges, P. D., Meng, Y., Strom, S. P., Blauwendraat, C., Lohmann, K., Casaceli, C., Rao, S. C., Ghosh Galvelis, K., Naito, A., Beck, J. C., & Alcalay, R. N.
- Affiliations
- Indiana University School of Medicine (US)
- Parkinson's Foundation (US)
- Columbia University Irving Medical Center (US)
- Cleveland Clinic (US)
- Northwestern University (US)
- Struthers Parkinson’s Center, Golden Valley , MN 55427 , USA
- Massachusetts General Hospital (US)
- Icahn School of Medicine at Mount Sinai (US)
- University of California San Diego (US)
- University of Kansas Medical Center (US)
- Barrow Neurological Institute (US)
- University of Miami (US)
- University of Pennsylvania (US)
- Department of Neurology, Baylor College of Medicine , Houston, TX 77030 , USA
- Centro Cardioneuro Oftalmológico y Trasplante , Santo Domingo 10306, República Dominicana
- Medicina Interna, Clínica Unión Médica del Norte , Santiago de los Caballeros 51000, República Dominicana
- Oregon Health & Science University (US)
- Temple Lung Center (US)
- Illumina (United States) (US)
- National Institutes of Health (US)
- University of Lübeck (DE)
- University of Rochester Medicine (US)
- Parkinson’s Foundation , NewYork, NY 10018 , USA
- Corresponding author
- Alcalay, Roy N
- ORCID
- Cook, Lola
- Verbrugge, Jennifer
- Schwantes-An, Tae-Hwi
- Schulze, Jeanine
- Foroud, Tatiana
- Marder, Karen S
- Mata, Ignacio F
- Mencacci, Niccolò E
- Nance, Martha A
- Schwarzschild, Michael A
- Simuni, Tanya
- Bressman, Susan
- Wills, Anne-Marie
- Fernandez, Hubert H
- Litvan, Irene
- Lyons, Kelly E
- Shill, Holly A
- Singer, Carlos
- Tropea, Thomas F
- Katus, Linn
- Quinn, Joseph F
- Hodges, Priscila D
- Meng, Yan
- Strom, Samuel P
- Blauwendraat, Cornelis
- Lohmann, Katja
- Rao, Shilpa C
- Naito, Anna
- Beck, James C
- Alcalay, Roy N
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2024-07-30
- Volume
- 147
- Issue
- 8
- Pages
- 2668-2679
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC11292896
- OpenAlex
- W4401158013
- Cited by
- 108
- References
- 28
- Citations by year
- 2026: 44 · 2025: 55 · 2024: 9
- FWCI
- 28.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- IUScholarWorks (Indiana University) (submittedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- Parkinson’s Foundation
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkinson's disease, genetic testing, genetic counseling, LRRK2, GBA1, Parkin, SNCA, PINK1, DJ-1, VPS35, genetic risk variants, genetic aetiology, genetic ancestry, early-onset Parkinson's disease, North America, Puerto Rico, Dominican Republic
- MeSH terms
- Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Protein Deglycase DJ-1, PTEN-Induced Putative Kinase, Adult, Aged, Canada, Female, Genetic Counseling, Genetic Testing, Glucosylceramidase, Humans, Male, Middle Aged, North America, Parkinson Disease, Protein Kinases, United States, Genetic Variation, Genetic Predisposition to Disease, Disclosure, Vesicular Transport Proteins, Ubiquitin-Protein Ligases, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.